Ocular Therapeutix
OCULOcular Therapeutix is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye.
Earnings
Next report
Nov 3, 2026 (Tomorrow)Valuation & ratios
Segments
By segment
Competitors
By market cap
By revenue growth
By net margin
Profile
Ocular Therapeutix is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye. The company leverages its proprietary hydrogel platform technology to create sustained-release drug delivery systems that aim to replace traditional topical eye drops with more effective, physician-administered treatments.
The company is a specialized player in the ophthalmic drug delivery space, transitioning from a device-focused firm to a pharmaceutical-led commercial entity with a focus on sustained-release technology.
FAQ
- What is Ocular Therapeutix's market cap?
- Ocular Therapeutix (OCUL) has a market capitalization of $1.6B and trades on NASDAQ.
- What is Ocular Therapeutix's revenue and profitability?
- Ocular Therapeutix generated $52.1M in trailing twelve-month revenue with a net loss of $301.4M, representing a net margin of -579.1%. Gross margin stands at 87.1%, with free cash flow of -$255.1M. The latest reported period is Q2 2026.
- Who are Ocular Therapeutix's competitors?
- Ocular Therapeutix's key competitors include Bausch + Lomb, Regeneron Pharmaceuticals, EyePoint, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Where is Ocular Therapeutix headquartered?
- Ocular Therapeutix is headquartered in United States of America and employs approximately 267 people. It has been publicly traded since 2014.
